Biopsy Devices Market Biopsy Devices Market: Empowering Early Intervention in the Fight Against Cancer

Biopsy Devices Market worth $20.04 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Biopsy Devices Market- (By Product Type (Needle Biopsy Devices (Guidance Systems, Biopsy Consoles, Site Markers, Biopsy Guns (Automated Systems, Semi-Automated Systems), Needles), Skin Biopsy Devices (Punch Biopsy Instruments, Shave Biopsy Instruments), Consumables (Forceps, Trocars, Trays, Other Consumables), By Biopsy Type (Tissue Biopsy (Needle Biopsy, Surgical Biopsy, Skin Biopsy), Liquid Biopsy),

By Anatomy (Breast, Lung, Bone, Liver, Uterus/Cervix/, Abdomen, Prostate, Cardiac, Skin, Others), By Disease Type (Cancer, Infections, Autoimmune Disorders, Non-Cancerous Indications, Others), By Guidance Technique (Growth-Share Analysis, Ultrasound-Guided Biopsy, X-Ray-Guided Biopsy, MRI-Guided Biopsy, CT-Guided Biopsy)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Biopsy Devices Market is valued at US$ 6.03 Bn in 2022, and it is expected to reach US$ 20.04 Bn by 2031, with a CAGR of 14.39% during the forecast period of 2024-2031.

Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/2228

A biopsy is a medical procedure that plays a vital role in identifying and removing potentially cancerous tissue. This test involves extracting tissue samples from a suspicious area to diagnose cancer. Various biopsy techniques exist, such as skin biopsy, vacuum biopsy, incisional and excisional biopsies, fine needle aspiration, and shave biopsy.

The global rise in cancer cases across various types has significantly driven the demand for improved care and awareness of screening and diagnostic tools. As a result, the need for biopsy devices is expected to experience a significant surge in the coming years.

Several factors are fueling this growth in the biopsy market. Firstly, the increasing incidence of cancers, particularly lung, prostate, and breast cancer, directly translates into a higher demand for biopsy procedures. Secondly, rapid advancements in biopsy technology, like 3D optical biopsies, MRI-targeted biopsies, and ultrasound-guided biopsies, are further propelling market growth. Finally, the growing understanding of chronic disease diagnosis necessitates the need for integrated biopsy technologies like stereotactic-guided biopsies. These factors collectively contribute to a promising outlook for the biopsy market.

List of Prominent Players in the Biopsy Devices Market:

• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Micronoma
• QIAGEN
• Revvity, Inc.
• Sysmex Corporation
• Thermo Fisher Scientific Inc
• Argon Medical Devices, Inc.
• B. Braun SE
• Becton
• Dickinson and Company
• Boston Scientific Corporation
• Cardinal Health, Inc.
• Cook Group Incorporated
• Conmed Corporation
• FUJIFILM Holdings Corporation
• GE Healthcare
• Inrad, Inc.
• Medtronic plc
• Olympus Corporation
• Siemens Healthineers AG
• Stryker Corporation
• Zamar Care
• Changzhou Jiuhong Medical Instrument Co., Ltd.
• Kindly (KDL) Meditech
• Ningbo Xinwell Medical Technology Co., LTD.
• Shenzhen Manners Technology Co., Ltd.
• Zhejiang Soudon Medical Technology Co., Ltd
• Agilent Technologies, Inc.
• BGI Group
• Biocept, Inc.
• Bio-Rad Laboratories, Inc.
• Dxcover Limited
• Elypta Limited

Market Dynamics:

Drivers-
Various dynamic aspects drive the biopsy device market's growth, trends, and innovations. These dynamics result from the changing healthcare landscape, technological improvements, legislative changes, and the rising prevalence of chronic diseases. There has been a huge increase in the number of cancer patients worldwide.

According to GLOBOCAN predictions, the number of cancer patients is predicted to rise to 19.3 million by 2025, up from 19.3 million in 2020. Cancer is the second biggest cause of death in the United States, accounting for approximately one out of every four deaths. According to the American Cancer Society, more than 1,688,000 new cancer cases (excluding carcinoma in situ of any location) are predicted to be diagnosed in the United States in 2017, with 600,920 cancer-related deaths expected in the same year; this amount translates to 1,650 deaths per day.

Challenges:
The expensive cost of biopsy instruments limits market expansion. Furthermore, clinical difficulties in core needle biopsy and an increase in complaints about breast cancer screening procedures are expected to impact the biopsy instruments market throughout the projection period. Moreover, biopsy methods help radiologists and surgeons examine anomalies at a specific spot. However, because these procedures include cuts and incisions for obtaining tissue samples, patients can become infected. The increased risk of infection following biopsy operations may stifle market growth.

Regional Trends:
The North America Biopsy Devices Market is expected to register a major market share in terms of revenue, and it is projected to grow at a high CAGR in the near future due to the significant availability of qualified medical personnel, availability of well-developed infrastructure facilities, and the presence of most of the essential stakeholders. Asia-Pacific is expected to experience substantial growth throughout the projected timeframe due to its sizable population, rising disposable income, and heightened patient awareness of disease screening. Furthermore, an increase in the senior population, which is extremely susceptible to cancer, is a major driver of the region's market growth.

Curious About This Latest Version of The Report? Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/2228

Recent Developments:

• In Sept 2023, A revolutionary collaboration has been declared between Roche France, Foundation Medicine, and the Institute Gustave Roussy to provide cancer patients in France with in-house liquid biopsy genomic testing. By transferring FoundationOne®Liquid CDx technology to the Institute Gustave Roussy, Roche France and Foundation Medicine have the potential to provide liquid biopsy testing for comprehensive genomic profiling (CGP) in all patients in France diagnosed with advanced cancer.

• In August 2022, Mammotome announced the release of the Mammotome DualCoreTM biopsy system, the company's first twin-stage core biopsy tool. This novel core biopsy device adds to the Mammotome ultrasound-guided breast biopsy portfolio, which already includes the Mammotome® Elite Tetherless Vacuum-Assisted Biopsy Device (tetherless VABB) and the Mammotome RevolveTM Dual Vacuum-Assisted Breast Biopsy System (tethered VABB).

Segmentation of Biopsy Devices Market-
By Product Type-
• Needle Biopsy Devices
o Guidance Systems
o Biopsy Consoles
o Site Markers
o Biopsy Guns
 Automated Systems
 Semi-Automated Systems
o Needles
• Skin Biopsy Devices
o Punch Biopsy Instruments
o Shave Biopsy Instruments
• Consumables
o Forceps
o Trocars
o Trays
o Other Consumables
By Biopsy Type
• Tissue Biopsy
o Needle Biopsy
o Surgical Biopsy
o Skin Biopsy
• Liquid Biopsy
By Anatomy-
• Breast
• Lung
• Bone
• Liver
• Uterus/Cervix/
• Abdomen
• Prostate
• Cardiac
• Skin
• Others
By Disease Type-
• Cancer
• Infections
• Autoimmune Disorders
• Non-Cancerous Indications
• Others
By Guidance Technique -
• Growth-Share Analysis
• Ultrasound-Guided Biopsy
• X-Ray-Guided Biopsy
• MRI-Guided Biopsy
• CT-Guided Biopsy
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/report/biopsy-devices-market/2228

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.